Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07561294
PHASE2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

Sponsor: ModernaTX, Inc.

View on ClinicalTrials.gov

Summary

This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.

Official title: A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

350

Start Date

2026-04-29

Completion Date

2028-11-09

Last Updated

2026-05-28

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

mRNA-1982

Suspension for injection

BIOLOGICAL

Placebo

Suspension for injection

Locations (8)

Colchester Research Group

Truro, Nova Scotia, Canada

Bluewater Clinical Research Group Inc.

Sarnia, Ontario, Canada

Stouffville Medical Research Institute Inc.

Stouffville, Ontario, Canada

Dr. Anil K. Gupta Medicine Professional Corporation Inc.

Toronto, Ontario, Canada

Diex Recherche Inc. - Division Joliette

Joliette, Quebec, Canada

Diex Recherche Inc. - Division Sherbrooke

Sherbrooke, Quebec, Canada

Diex Recherche Inc. - Division Victoriaville

Victoriaville, Quebec, Canada

Diex Recherche Inc. - Division Quebec

Québec, Canada